Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Am J Obstet Gynecol. 2015 Aug 10;214(1):99.e1–99.e8. doi: 10.1016/j.ajog.2015.08.011

Figure 2.

Figure 2

Figure 2

Upper Panel. Solitomab (EpCAM BiTE®) cytotoxicity titration graph for USPC-ARK-2. Doses from 0 to 2.5 µg/ml were used in several cytotoxicity experiments aimed at determining the optimum dose of solitomab. As a results of these experiments the 1µg/ml concentration was selected as optimal for the additional cytotoxicity assays. Lower Panel. Graph showing antibody-dependent cell-mediated cytotoxicity for five representative USC cell lines in control conditions and with solitomab at two effector: target ratios. As expected, the higher effector: target ratio of 1:20 (i.e., the ratio of T lymphocyte effector cells vs number of tumor target cell used in the assay) demonstrated higher cytotoxicity results.